Morphogenesis, a clinical-stage biotechnology company, agreed to merge with CohBar, a clinical-stage biotechnology company, in a $15m deal. “Following a thorough review and evaluation, we believe merging with Morphogenesis and leveraging their late-stage pipeline of novel immuno-oncology technologies represents the best path forward for our stockholders and has the potential to deliver near and long-term value. Our board and management team believe that the combined company will be well-positioned to develop powerful new therapies with the potential to overcome resistance to current immunotherapies, an area of significant unmet need," Joseph Sarret, CohBar CEO.